Stock Analysis of Krystal Biotech Inc (KRYS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code KRYS
Close 160.05
Change -1.55 / 0.959 %
Volume 187581
Vol Change -11305.00 / 5.68 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index No Significant Growth
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Krystal Biotech Inc
PE (TTM)

18720.63

Very Poor
Price / Book

1539.03

Very Poor
Price / Sales

11152.69

Very Poor
Piotroski F Score

6.0

Good
Market Cap

4570.77 M

Enterprise Value

4213.92 M

ROA (TTM)

7.77

Indecisive
ROE (TTM)

8.22

Not Good
Net Margin (TTM)

59.57

Excellent
Revenue

%

50699.00 K
Net Profit

107.81 %

10932.00 K
Debt to Equity

0.0019

Excellent
Altman Z Score

69.08

Excellent
Quick Ratio

17.55

Excellent
Cash Ratio

16.08

Excellent


Highs/Lows of Krystal Biotech Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week162.83 1.71 % 0.513 % 164.54154.528-May-2429-May-24
Two Week164.1 2.47 % 0.486 % 174.495154.522-May-2429-May-24
One Month153.12 4.53 % 4.80 % 174.495144.022-May-2406-May-24
Three Month159.47 0.364 % 3.56 % 189.97144.005-Mar-2406-May-24
Six Months104.23 53.55 % 15.54 % 189.97100.9805-Mar-2406-Dec-23
One year117.85 35.81 % 26.26 % 189.9793.9805-Mar-2410-Nov-23
Two year58.88 171.82 % 27.72 % 189.9762.7805-Mar-2412-Oct-22
Five year31.42 409.39 % 91.77 % 189.9722.0205-Mar-2414-Jun-19


Technical View of Krystal Biotech Inc
RSI

47.50

Neutral
MACD

-0.499

Mild Bearish
ADX

12.78

Bullish
Super Trend

173.41

Mild Bearish
Williams %R

-72.17

Neutral
CCI

-2.20

Neutral


EMA 5

160.59

Neutral
EMA 15

161.44

Strong Bearish
EMA 50

160.49

Whipsaw
EMA 100

152.24

Bullish
SMA 100

151.15

Bullish
SMA 200

133.04

Bullish
SMA 5 / 20

159.97 / 161.02

Strong Bearish
SMA 15 / 50

161.61 / 165.78

Mild Bearish
SMA 50 / 200

165.78 / 133.04

Strong Bullish




Charts of Krystal Biotech Inc


Returns of Krystal Biotech Inc with Peers
Period / StockKRYSINSPMMSICRSP
1 Week-1.71%0.0441%-0.940%-2.72%
1 Mth4.53%-34.29%9.51%1.42%
3 Mth0.364%-11.31%6.50%-36.19%
6mth53.55%9.28%13.40%-19.47%
1 Year35.81%-45.71%-1.52%-16.08%
2 Year171.82%-10.20%32.19%-7.42%
5 Years409.39%181.19%57.18%51.08%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Krystal Biotech Inc with Peers
Ratio / StockKRYSINSPMMSICRSP
PE18720.63-298.8546.53-19.82
P/B1539.038.585.572.30
ROA7.77-2.466.22-9.70
ROE8.22-2.878.43-11.59
Debt To Equity0.001900.6950.0083
Revenue50699.00 K
% 		570191 K
39.80 % 		1226.27 M
6.54 % 		170006 K
38892.20 %
Net Income10932.00 K
107.81 % 		-32766.00 K
26.99 % 		100183 K
34.44 % 		-353532.00 K
45.63 %


Technicals of Krystal Biotech Inc with Peers
Technical / StockKRYSINSPMMSICRSP-
ADX12.7839.4637.6513.36
CMF0.052-0.218-0.066-0.177
MFI52.7140.2551.7346.07
RSI47.5036.7156.7141.47
MACD Abv SignalFalseTrueFalseTrue
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MATrueFalseTrueFalse-


About : Krystal Biotech Inc

Address : 2100 Wharton Street, Pittsburgh, PA, United States, 15203
Tel : 412 586 5830
URL : https://www.krystalbio.com
Code : KRYS, ISIN : US5011471027, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 20_Sep_2017
Employee Count : 229

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)